Francisco V Muñoz1, Linda Larkey2. 1. Arizona State University, College of Nursing and Health, Innovation Pomona Valley Hospital Medical Center, Lewis Family, Cancer Care Center. 2. Arizona State University, College of Nursing and Health Innovation.
Abstract
BACKGROUND: Biomarkers associated with inflammation and immune function are increasingly being used to examine mechanisms of the effects of mind-body therapies. Less researched are biomarkers associated with cognitive and executive functioning in the study of mind-body therapy mechanisms and effects. This study explored the feasibility of recruiting breast cancer patients (BCPs) and implementation fidelity of participation in a research project utilizing the 4-stage Creative Psychosocial Genomic Healing Experience (CPGHE), a mind-body protocol that is theorized to create epigenetic effects via targeted psychological change in emotional triggers in coping with cancer. METHODS: Eight BCPs were identified as eligible (stages I, II, III, early phases of treatment) and five consented to one of two intervention groups (allocated to a single session or two sessions of CPGHE). Blood draws were examined pre- and post- intervention for a stress/inflammation gene expression marker, Nuclear Factor kappa-B (NF-kB), and three markers associated with synaptic plasticity undergirding cognitive and executive functioning: Early Growth Response 1 (EGR1), activity-regulated cytoskeleton-associated protein (Arc), and brain-derived neurotrophic factor (BDNF). RESULTS: One consented BCP dropped out due to illness. The remaining four adhered to the 4-stage CPGHE protocol and found the CPGHE experience beneficial. Blood samples for the gene expression results were collected and processed according to planned protocol without incident. CONCLUSION: Implementing the CPGHE and achieving good adherence among a sample of BCPs is feasible. Processing of blood samples collected from BCPs for gene expression data is also feasible.
BACKGROUND: Biomarkers associated with inflammation and immune function are increasingly being used to examine mechanisms of the effects of mind-body therapies. Less researched are biomarkers associated with cognitive and executive functioning in the study of mind-body therapy mechanisms and effects. This study explored the feasibility of recruiting breast cancer patients (BCPs) and implementation fidelity of participation in a research project utilizing the 4-stage Creative Psychosocial Genomic Healing Experience (CPGHE), a mind-body protocol that is theorized to create epigenetic effects via targeted psychological change in emotional triggers in coping with cancer. METHODS: Eight BCPs were identified as eligible (stages I, II, III, early phases of treatment) and five consented to one of two intervention groups (allocated to a single session or two sessions of CPGHE). Blood draws were examined pre- and post- intervention for a stress/inflammation gene expression marker, Nuclear Factor kappa-B (NF-kB), and three markers associated with synaptic plasticity undergirding cognitive and executive functioning: Early Growth Response 1 (EGR1), activity-regulated cytoskeleton-associated protein (Arc), and brain-derived neurotrophic factor (BDNF). RESULTS: One consented BCP dropped out due to illness. The remaining four adhered to the 4-stage CPGHE protocol and found the CPGHE experience beneficial. Blood samples for the gene expression results were collected and processed according to planned protocol without incident. CONCLUSION: Implementing the CPGHE and achieving good adherence among a sample of BCPs is feasible. Processing of blood samples collected from BCPs for gene expression data is also feasible.
Authors: Gustav Dobos; Tatiana Overhamm; Arndt Büssing; Thomas Ostermann; Jost Langhorst; Sherko Kümmel; Anna Paul; Holger Cramer Journal: Support Care Cancer Date: 2015-02-26 Impact factor: 3.603
Authors: Michael R Irwin; Richard Olmstead; Elizabeth C Breen; Tuff Witarama; Carmen Carrillo; Nina Sadeghi; Jesusa M G Arevalo; Jeffrey Ma; Perry Nicassio; Patricia A Ganz; Julienne E Bower; Steve Cole Journal: J Natl Cancer Inst Monogr Date: 2014-11
Authors: Icro Meattini; Isacco Desideri; Giulio Francolini; Agnese Vannini; Marco Perna; Pietro Garlatti; Roberta Grassi; Lorenzo Livi Journal: Med Oncol Date: 2017-03-31 Impact factor: 3.064
Authors: Kerstin Hermelink; Markus Bühner; Philipp Sckopke; Franziska Neufeld; Judith Kaste; Varinka Voigt; Karin Münzel; Rachel Wuerstlein; Nina Ditsch; Karin Hellerhoff; Dorothea Rjosk-Dendorfer; Michael Braun; Franz Edler von Koch; Kristin Härtl; Stephan Hasmüller; Ingo Bauerfeind; Gerlinde Debus; Peter Herschbach; Sven Mahner; Nadia Harbeck Journal: J Natl Cancer Inst Date: 2017-10-01 Impact factor: 13.506
Authors: Alexandra C Apple; Anthony J Ryals; Kathryn I Alpert; Lynne I Wagner; Pei-An Shih; Mehmet Dokucu; David Cella; Frank J Penedo; Joel L Voss; Lei Wang Journal: Neuroimage Clin Date: 2017-03-16 Impact factor: 4.881
Authors: Shirley S M Fong; Anna W M Choi; W S Luk; Timothy T T Yam; Joyce C Y Leung; Joanne W Y Chung Journal: Integr Cancer Ther Date: 2017-01-04 Impact factor: 3.279